Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | 3004043 | PO / MO |
The patient took first and second dose of Vivotif vaccine in two consecutive days instead of skipping day; Case reference number US-BN-2024-002164 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV24-1593) on 08-Jul-2024 and concerns a 21-year-old female patient. The patient's medical history and concomitant medication details were not provided. On 06-Jul-2024, the patient took the first dose of Vivotif vaccine (batch number: 3004043), at an unknown dose, orally for typhoid immunization. On 07-Jul-2024, one day after first dose of Vivotif vaccine, the patient took the second dose of Vivotif vaccine (batch number: 3004043), at an unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). As reported, the patient knew that doses were every other day, but mistakenly took one of the doses in two consecutive days, instead of skipping day. At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240708-904e8f to US-BAVARIAN NORDIC A/S-US-BN-2024-002164, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A 21-year-old female patient took the second dose of Vivotif vaccine one day after first dose of Vivotif which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 21-year-old female patient took the second dose of Vivotif vaccine one day after first dose of Vivotif which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious. USBAV24-1593:
Comments: None